Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
checkpoint inhibitors
Biotech
Sensei lays off 46% of staff, closes site to fund cancer trial
Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to take its immune checkpoint inhibitor though phase 2.
James Waldron
Nov 14, 2024 9:38am
BioNTech pays $800M to take control of potential Keytruda killer
Nov 13, 2024 6:45am
Crescent inks GlycoMimetics merger, securing listing and $200M
Oct 29, 2024 10:20am
Merck's LAG-3 combo fails colorectal cancer phase 3 study
Sep 25, 2024 8:35am
ESMO: Innovent links cytokine to colorectal cancer responses
Sep 18, 2024 9:53am
Incyte drops two PD-L1 drugs as part of 2nd pipeline clear-out
Jul 30, 2024 8:14am
